Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PLACEBO Clear all

Conditions: Candida Vulvovaginitis
Interventions: Ibrexafungerp, Placebo; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 20 more

Conditions: Obesity, Healthy
Interventions: Ileocolonic-release conjugated bile acid, Placebo; Dietary Supplement · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Progressive Supranuclear Palsy
Interventions: Tolfenamic Acid, Placebos; Drug
Lead sponsor: NeuroTau, Inc.; Other
Eligibility: 40 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Asthma
Interventions: RPT193, Placebo; Drug · Other
Lead sponsor: RAPT Therapeutics, Inc., a member of the GSK plc group of companies; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 13
States / cities: San Jose, California • Stockton, California • Westminster, California + 9 more

Conditions: Overactive Bladder
Interventions: Mirabegron 50 MG, Posterior Tibial Nerve Stimulation (PTNS); Drug · Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Alcohol Use Disorders
Interventions: Ibudilast, Matched placebo; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Constipation
Interventions: polyethyleneglycol3350; Drug
Lead sponsor: Braintree Laboratories; Industry
Eligibility: 4 Years to 16 Years
Enrollment: 100 participants
Timeline: Started 2003
U.S. locations: 3
States / cities: Boston, Massachusetts • Morristown, New Jersey • Pittsburgh, Pennsylvania

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions: Bimekizumab, Ustekinumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 25
States / cities: Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more

Conditions: Obstetric Labor, Premature, Venous Thrombosis
Interventions: Nifedipine; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: Belcesiran, Placebo; Drug · Other
Lead sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: La Jolla, California • Gainesville, Florida • Charleston, South Carolina

Conditions: Spondylitis, Ankylosing
Interventions: Secukinumab, Placebo (Pbo); Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 5
States / cities: Portland, Oregon • Duncansville, Pennsylvania • Jackson, Tennessee + 2 more

Conditions: Overweight, Autism Spectrum Disorder
Interventions: Metformin, Placebo; Drug
Lead sponsor: Holland Bloorview Kids Rehabilitation Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Columbus, Ohio • Pittsburgh, Pennsylvania • Nashville, Tennessee

Conditions: Tobacco Use Disorder
Interventions: placebo, 2 mg nicotine polacrilex; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 16 Years to 50 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 4
States / cities: Farmington, Connecticut • Hartford, Connecticut • New Britain, Connecticut + 1 more

Conditions: Chronic Pancreatitis, Exocrine Pancreatic Insufficiency
Interventions: Placebo, EUR-1008 (APT-1008) High Dose, EUR-1008 (APT-1008) Low Dose; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 6 more

Conditions: Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia, Superimposed Pre-Eclampsia, Cardiovascular Complication
Interventions: Placebo, Dapagliflozin 10mg Tab; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Norovirus Prevention
Interventions: Norovirus Bivalent VLP Vaccine, Placebo (Saline); Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 454 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Coral Gables, Florida + 6 more

Conditions: ASD
Interventions: L-DOPA versus Placebo, Social Skills Training; Drug · Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 13 Years to 30 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: People With Identified Painful Trigger Points (Tp) Within the Soleus and Gastrocnemius Muscles Complex, Healthy Subjects or Volunteers
Interventions: Dry needling with electrical stimulation, Dry needling, Electrical stimulation, Sham; Procedure
Lead sponsor: University of Rhode Island; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Kingston, Rhode Island

Conditions: Dyslipidaemia
Interventions: TAP311 capsules, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Pathologic Skin Picking, Neurotic Excoriation, Psychogenic Excoriation, Dermatillomania
Interventions: N-Acetyl Cysteine, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 64 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Erectile Dysfunction
Interventions: Tamsulosin and avanafil, Doxazosin and avanafil; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Diabetic Neuropathy, Painful
Interventions: PF-05089771 150 mg, Matched placebo for PF-05089771 150 mg and pregabalin 300 mg, Pregabalin 300 mg, PF-05089771 150 mg + Pregabalin 300 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 32
States / cities: Phoenix, Arizona • Fresno, California • Bradenton, Florida + 24 more

Conditions: Pneumonitis, SARS-CoV Infection
Interventions: GLS-1027, Placebo; Drug
Lead sponsor: GeneOne Life Science, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Peripheral Neuropathy, Pain, Neuropathic, Diabetes
Interventions: Moxibustion - Traditional (Active), Moxibustion - Smokeless - (Active), Placebo Moxibustion; Other
Lead sponsor: New York University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: New York, New York

Search by objective public record fields.

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

Effect of Bile Acids on Satiety, Cell Function and Body Weight in Patients With Obesity and Abnormal Satiety Phenotype

Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks

Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)

Development of Ibudilast for Alcohol Use Disorder

PolyethyleneGlycol3350 Laxative vs Placebo in Constipated Children

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Nifedipine vs Placebo for Maintenance Tocolysis of Preterm Labor.

A Study of Belcesiran in Patients With AATLD

Extension in AS: Sustainability of Benefits, Safety and Tolerability

Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)

Nicotine Replacement Treatment for Pregnant Smokers - 1

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD

Trigger Point Dry Needling With and Without Electrical Stimulation in Healthy Subjects

Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

N-Acetyl Cysteine in Pathologic Skin Picking

Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin

A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)

GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)

Distal Peripheral Neuropathy in Type 2 Diabetes